Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

poster presentations, Poniard will host an investor event on Sunday, June 1, at 6:30 p.m. in Chicago. The event will feature presentations and discussion with expert oncologists, including lung cancer expert Chandra Belani, M.D., of the University of Pittsburgh Medical Center; prostate cancer expert E. David Crawford, M.D., of the University of Colorado Health Sciences Center in Denver; and platinum therapy developer, Lloyd Kelland, Ph.D., of Cancer Research Technology and University College London, in addition to members of Poniard's senior management. For more information or to rsvp to the event, please email rsvp@poniard.com.

About Picoplatin

Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. The Company is also evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of HRPC, and an ongoing Phase 2 clinical trial in patients with patients with metastatic CRC. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. The oral formulation of picoplatin has the same active pharmaceutical ingredient as the intravenous formulation. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biop
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... a sweeping analysis assessing the current state of diabetes ... conclude that there remains considerable room for improving treatment ... but especially for adolescents and young adults. The analysis ... the need to address barriers to care and implement ... patients achieve optimal metabolic control. The ...
(Date:5/21/2015)... Research and Markets ... of the "North American Joint Reconstruction ... Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... at $4,470.9 million in 2014 and is ...
(Date:5/21/2015)... , May 21, 2015 ... ) has announced the addition of the ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... analyze and size the world market for ... and identifies trends impacting the market for ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3
... MISSISSAUGA, Ontario, March 29, 2011 GlaxoSmithKline (GSK) and ... (TSX: VRX) announced today that the European Commission has ... (add-on) treatment of partial onset seizures (a form of ... in one side of the brain), with or without ...
... Metabolic Solutions Development Company (MSDC), a drug discovery ... treat metabolic diseases, announced today that it has ... company,s second drug candidate for the treatment of ... and placebo-controlled clinical trial will involve approximately 125 ...
Cached Medicine Technology:GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 2GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 3GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 4GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 5Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 Scientists with ... paper on air quality compliance issues that may have ... workers. Surviving Mesothelioma has just posted an article on ... , The group found airborne asbestos levels well ... collected between 1984 and 2011. , “Asbestos compliance sampling ...
(Date:5/24/2015)... New York (PRWEB) May 24, 2015 ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled its ... progress of the multidistrict litigation. According to court ... District of Illinois, the Conference will be convened ... re: Testosterone Replacement Therapy Product Liability Litigation - ...
(Date:5/24/2015)... Indianapolis, Indiana (PRWEB) May 24, 2015 ... network service provider announces Midwest Telecom of America, Inc. ... , According to Cory Childs, IFN Enterprise Sales ... to service providers. “IFN’s fiber transport provides MTA ... Operations Center to their Tier 1 Internet and voice ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2
... Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain ... King Extends Tender Offer Through December 19, 2008 ... N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: KG ... that the two companies have signed a definitive merger agreement under ...
... Nov. 24 Transdel,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and commercialization of non-invasive,topically targeted medications, today announced ... Company,s Board of Directors. , ... Swann, Inc., a consulting firm specializing in,marketing and ...
... resorts,are opening for the season, the Kelly Brush Foundation kicked ... the announcement of,over $20,000 in grants to ski racing clubs ... campaign to promote and improve ski racing safety. , ... of the most prestigious racing programs in,the nation including the ...
... DaVita Inc., a,leading provider of kidney care services ... kidney failure, continues to enhance DaVita.com to,make it ... well as a valuable,resource for patient education. DaVita.com/physicians ... people with chronic kidney disease and can,be found ...
... 24 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced that the first three ... completed by Dr. Allan,Stewart, Director, Aortic Surgery Program ... York ( http://www.ctsnet.org/home/allanstewart ) on November 17,and 18, ...
... ,Tis may be the season to be jolly but,tis ... lines that,barely move and public places stuffed with wheezing, sneezing ... makes keeping fit and healthy a bit of a challenge. ... find,Life123.com a comforting, mouse-click away. If you feel a ...
Cached Medicine News:Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 2Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 3Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 4Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 5Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 6Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 7Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 8Health News:King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion 9Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 2Health News:Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors 3Health News:Kelly Brush Foundation Awards Ski Racing Safety Grants 2Health News:DaVita.com Launches Physician Website 2Health News:DaVita.com Launches Physician Website 3Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 2Health News:ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States 3Health News:Staying Healthy This Holiday Season Can be as Easy as Life123 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: